Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
The FDA has approved Xtampza ER (Collegium), a new extended-release, abuse-deterrent capsule formulation of oxycodone, for management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Five other abuse-deterrent opioid formulations were approved earlier, three as single-drug products and two in combinations with opioid antagonists.1 Two of these products, Morphabond (morphine ER) and Targiniq ER (oxycodone ER/naloxone), have not yet been marketed. Zohydro ER (hydrocodone ER) was reformulated in 2015 to make abuse more difficult, but it has not received FDA approval as an abuse-deterrent opioid. No studies are available comparing the relative safety of these products.
A New Abuse-Deterrent Opioid—Xtampza ER. JAMA. 2016;316(9):986–987. doi:10.1001/jama.2016.9540
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: